|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.JP |
First Approval Date01 Nov 1956 |
|
MechanismGABAA receptor agonists |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date28 Apr 1955 |
Target- |
Mechanism- |
Active Org.- |
|
Active Indication- |
Inactive Indication- |
Drug Highest PhaseWithdrawn |
First Approval Ctry. / Loc.US |
First Approval Date01 Jan 1982 |
Active-Controlled Trial of the Safety and Tolerability of MP29-02 in Subjects with Chronic Allergic or Nonallergic Rhinitis
Active-Controlled Trial of the Safety and Tolerability of MP03-33 in Patients with Chronic Allergic or Nonallergic Rhinitis - NA
Active-Controlled Trial of the Safety and Tolerability of MP03-33 (Nasal Spray) in Patients with Chronic Allergic or Nonallergic Rhinitis
100 Clinical Results associated with Medpointe Pharmaceuticals
0 Patents (Medical) associated with Medpointe Pharmaceuticals
100 Deals associated with Medpointe Pharmaceuticals
100 Translational Medicine associated with Medpointe Pharmaceuticals